PharmaCyte Biotech, Inc.
PMCB
$0.94
$0.044.34%
NASDAQ
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.42M | -8.36M | 11.75M | -3.05M | -1.47M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.31M | 7.32M | -14.05M | 2.11M | 864.20K |
| Change in Net Operating Assets | 129.70K | -954.80K | 1.26M | 422.20K | -449.30K |
| Cash from Operations | -979.50K | -1.99M | -1.04M | -509.90K | -1.05M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3.00M | -- | 0.00 | 0.00 | 0.00 |
| Cash from Investing | -3.00M | -- | 0.00 | 0.00 | 0.00 |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -171.50K | -225.00K | -1.40M |
| Issuance of Preferred Stock | 6.27M | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | 0.00 | -3.72M | -9.34M |
| Total Dividends Paid | -61.30K | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 6.21M | -- | -171.50K | -3.95M | -10.74M |
| Foreign Exchange rate Adjustments | -400.00 | 100.00 | 600.00 | -1.20K | 100.00 |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.23M | -1.99M | -1.21M | -4.46M | -11.80M |